< back to Overview

Braingineering Technologies

Download Presentation

Video Presentation

Dr Stephanie Smith-Eckhardt, Prof. Jens Schwamborn, Dr Silvia Bolognin

Braingineering Technologies

Innovation & Business Idea
We are observing exploding R&D costs in the central nervous system (CNS), while inadequate in vitro and rodents models are applied in the neurodegenerative disease field. Accordingly, there is an urgent need to find models that mimic the complex human brain to improve the success rate of new drug candidates.
“Braingineering” is a new high-tech Brain-on-a-Chip technology that uses the iPSC method to populate neurons and/or astrocytes in microfluidics devices to screen drug candidates in vitro. Added value is provided by: 1) mimicking adequately the human disease, 2) reducing animal testing, 3) ability of medium throughput, 4) relatively low costs due to less media.

Customers/Target Market
We have identified a huge market potential:
Our customers are large pharmaceutical companies as well as specialized biotech companies.
The drug discovery and preclinical outsourcing market is predicted to grow at a CAGR of 7% in the next 5 years. The market size will be $6 billion in 2018 with a penetration rate of up to 60%.
There is no existing cure for Parkinson’s disease, while the growth of affected cases is estimated to be 3% (2013-2018), which leads to about 16 million individuals in 2020.

Competitors
There is no company that offers Brain-on-a-Chip drug screening. However, we monitor all those companies that apply the 3D cell culture technology to other organs than the brain and consider them as serious competitors: Atera, Mimetas, TissUse, Emulate, Hurel, Livership, InSphero, Organovo.

Intellectual Property Status
The business is based on three patents that were filed in 2015.

Development Status & Future Steps
The company Braingineering Technologies S.à.r.l. was incorporated in February 2016. Currently, we are conducting two pilot projects with large pharmaceutical companies. In the future, we plan to continue our business activities in our own facilities.

Exit Strategy
Within the next 5 years, we expect that the company will be acquired.

Team Description
Dr Silvia Bolognin has long-standing experience in the field of neurodegeneration and tissue engineering with a focus on Alzheimer’s disease as well as on Parkinson’s disease.
Prof. Dr Jens Schwamborn holds a record of accomplishment in stem cell research and neuroscience. He is an expert for Parkinson’s disease research.
Dr Stephanie Smith-Eckhardt holds her PhD in economics and has work experience in IT and Business Strategy Consulting.

Financing Need
We require 750K€ to setup our own lab facilities and hire qualified staff. With this investment, we will manage to break-even with our service business model within two years.

Searching for
Commercial Partner, Funding, Collaboration

 

BioVaria 2017

22 - 23 May 2017, Munich

Join BioVaria, the marketplace for life-science inventions from leading European research institutions and universities.